Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AMGN save search
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Published: 2022-08-04 (Crawled : 12:20) - ir.chemocentryx.com
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 106.71%
H: 1.29%
C: 0.36%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.06%
H: 0.81%
C: -0.01%
acquire
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
ENTX | $2.11 -16.27% 440K
|
Health Technology
|
| O: 60.58%
H: 20.39%
C: -9.85%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
phase 2 topline eb613 dmd
FIRST REPUBLIC BANK (NYSE: FRC) INVESTIGATION ALERT: Bernstein Liebhard is investigating possible securities claims against First Republic Bank
Published: 2023-03-16 (Crawled : 21:00) - prnewswire.com
PHI | $23.045 -3.74% 47K
|
Communications
|
| O: 2.51%
H: 0.63%
C: -1.98%
FRC 4 d | $3.51 -45.9% 180M
|
Finance
|
| O: 41.84%
H: 0.0%
C: 0.0%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.43%
H: 0.1%
C: -1.62%
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.11 -16.27% 440K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 7.48%
H: 0.45%
C: -4.8%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.32%
H: 0.2%
C: -1.16%
rituxan fda biosimilar
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
Published: 2023-08-08 (Crawled : 12:00) - biospace.com/
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 5.42%
H: 2.43%
C: 1.27%
therapeutics financial results
AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING
Published: 2022-02-08 (Crawled : 14:00) - biospace.com/
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: -0.93%
H: 0.07%
C: -4.48%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 4.51%
H: 5.06%
C: 3.47%
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 4.23%
H: 6.03%
C: 2.76%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.33%
H: 0.52%
C: -0.47%
lumakras trial 100 cancer pancreatic
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 4.16%
H: 3.44%
C: -1.66%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.1%
H: 0.89%
C: 0.68%
topline positive phase 2
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | $135.94 770
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
VTRS | $11.15 -1.5% 2.3M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | $40.035 -1.15% 1.5M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PBYI | $5.07 -5.23% 200K
|
Health Technology
|
| O: -0.1%
H: 2.31%
C: -1.26%
AZN | $68.38 -0.51% 2.1M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.44%
H: 0.2%
C: -0.55%
drug breast expected cancer pipeline therapeutics growth market
LUMAKRAS® (sotorasib) Receives Approval In Japan For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2022-01-20 (Crawled : 11:00) - biospace.com/
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 3.95%
H: 2.8%
C: 1.37%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.07%
lumakras approval cel lung cancer cancer
Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 3.59%
H: 0.0%
C: 0.0%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.28%
H: 0.66%
C: -0.14%
cell global leukemia market
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published: 2022-08-30 (Crawled : 21:00) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 0.12%
H: 0.16%
C: -0.31%
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 1.03%
H: 0.95%
C: -0.53%
lumakras lung topline trial cancer
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Published: 2023-10-31 (Crawled : 11:00) - prnewswire.com
SNYNF | $92.966 630
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
XNCR | $19.08 -5.12% 170K
|
Health Technology
|
| O: -0.41%
H: 2.1%
C: 1.11%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
REGN | $895.57 -0.33% 180K
|
Health Technology
|
| O: -0.33%
H: 0.92%
C: 0.61%
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 0.14%
H: 0.68%
C: -0.32%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -2.77%
H: 0.6%
C: -0.07%
financial results
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
Published: 2024-02-26 (Crawled : 14:00) - prnewswire.com
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.31%
H: 0.55%
C: -0.66%
Cancer Supportive Care Market Size to Grow by USD 4.98 Billion | Market Research Insights Highlight Growing Prevalence of Cancer Cases as Key Driver | Technavio
Published: 2022-02-01 (Crawled : 05:00) - prnewswire.com
NVSEF | $93.6375 82K
|
Health Technology
|
| O: 3.58%
H: 0.0%
C: -1.59%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
GSK | $40.035 -1.15% 1.5M
|
Health Technology
|
| O: 0.45%
H: 0.53%
C: 0.42%
BAX | $39.79 -0.62% 1.3M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -0.77%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.39%
H: 0.24%
C: 0.19%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.22%
H: 0.91%
C: 0.68%
research cancer growing
Bispecific Antibodies for Cancer Market will Register 6.44% YOY Growth in 2022 | 39% Growth to Originate from North America| 17,000+ Technavio Reports
Published: 2022-03-09 (Crawled : 08:00) - prnewswire.com
ALPMY | $9.2715 500K
|
Manufacturing
|
| O: -2.55%
H: 1.28%
C: 0.19%
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: 8.24%
H: 1.25%
C: -1.99%
MRUS | $40.7 -1.38% 550K
|
Health Technology
|
| O: 0.5%
H: 5.19%
C: 4.84%
MREO | $2.65 -0.75% 330K
|
Health Technology
|
| O: 16.67%
H: 4.76%
C: -0.68%
APVO 3 d | $0.7694 -1.74% 450K
|
Health Technology
|
| O: -2.6%
H: 10.68%
C: 4.31%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.81%
H: 0.13%
C: -1.18%
AFMD | $5.3 -3.46% 22K
|
Health Technology
|
| O: 2.39%
H: 7.24%
C: 6.07%
america origin report cancer growth antibody
Rheumatoid Arthritis Drugs Market Size to Grow by USD 14.90 Billion | 37% of the growth will originate from Europe | Technavio
Published: 2022-06-24 (Crawled : 09:00) - prnewswire.com
ALPMF | $9.48 1.7K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -0.5%
GLAXF | $20.2 510
|
Health Technology
|
| O: 3.19%
H: 2.28%
C: -1.81%
SNYNF | $92.966 630
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 82K
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
ALPMY | $9.2715 500K
|
Manufacturing
|
| O: 4.33%
H: 0.0%
C: -2.44%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
GSK | $40.035 -1.15% 1.5M
|
Health Technology
|
| O: 1.26%
H: 0.95%
C: 0.92%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
GLMD | $0.333 -11.46% 60K
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: -3.5%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.37%
H: 0.82%
C: 0.56%
europe growth market drug
Key Players Such as AbbVie, Roche, and Amgen Dominate the Competitive Landscape of the Expanding Cytokine Market
Published: 2023-11-03 (Crawled : 01:00) - prnewswire.com
UCBJF | $126.05 100
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
UCBJY | $63.0 11K
|
Manufacturing
|
| O: 0.48%
H: 1.02%
C: 0.42%
TMO | $555.75 -0.38% 380K
|
Health Technology
|
| O: 2.32%
H: 0.0%
C: 0.0%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 1.88%
H: 0.0%
C: 0.0%
TECH | $64.23 -3.75% 460K
|
Health Technology
|
| O: 2.71%
H: 4.38%
C: 3.18%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.72%
H: 0.76%
C: 0.5%
ABCM | $23.99 0.0% 7.4M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
market
EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Published: 2022-01-10 (Crawled : 06:00) - prnewswire.com
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: 0.0%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: 0.0%
cancer
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.